TSTrisha Shang

Trisha Shang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Trisha Shang has a total of 216 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Total Laryngectomy Length of Stay Association With Diagnosis Related Group Classification

    by Trisha Shang, Claudia I. Cabrera, Rachel A. Kominsky, Nicole Fowler, Shawn Li, Jason E. Thuener, Pierre Lavertu, Theodoros N. Teknos, Rod P. Rezaee, Nicole Maronian, et al.

    Objective: With increased nationwide emphasis on high‐value care and cost reduction, more attention has been paid to postoperative outcomes. In this study, we examined if diagnosis related group (DRG) classifications could be used to predict total laryngectomy (TL) length of stay (LOS) which could help with determining areas for improved resource allocation. Methods: This is a retrospective study at a single tertiary academic center of TL patients between January 2013 and December 2020. For each DRG, we compared the primary outcome of LOS and secondarily examined perioperative outcomes, including complications and readmissions. We used Kruskal‐Wallis tests to assess perioperative outcome and LOS differences among DRGs' correlation. Furthermore, we used public data to determine annual geometric means LOS (GMLOS) for TLs and compared this to institutional LOS. Results: The 211 patients were included. Patients with more severe DRG classification had greater LOS ( p = 0.004). Fistula complications occurred at higher rates in more severe DRG classification, with major complication or comorbidity (MCC) at 25.0%, CC at 16.9%, and without complication or comorbidity (CC)/MCC at 3.1%, p = 0.02. The 30‐day readmission was more common in MCC (26%) compared to CC (8.4%) or without CC/MCC (9.4%), p < 0.01. We found higher GMLOS compared to institutional LOS for TLs. Conclusion: TL patients with CC and MCC have longer LOS than those without CC/MCC, as well as higher fistula and readmission rates. DRGs can be used to identify areas to improve resource allocation for patients that may have poorer post‐TL outcomes. Level of Evidence: 3


  • Open Access

    Clinical features, evaluation, and management of speech and swallow complications of facial paralysis: A scoping review

    by Mia Vargo, Peng Ding, Michelle E. Adessa, Radhika Duggal, Ravi Dhamija, Yiqing Tang, Trisha Shang, Katherine Wang, Mary Schleicher, Dane J. Genther, et al.


  • Outcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16‐Negative Oropharyngeal Cancers

    by Kaveh Zakeri, Steven D. Wren, Trisha Shang, Yao Yu, Linda Chen, Achraf Shamseddine, Amir H. Safavi, Jung Julie Kang, C. Jillian Tsai, Eric J. Sherman, et al.

    Background: Reducing elective nodal irradiation dose can decrease treatment toxicity and improve quality of life for head and neck cancer patients. Methods: We determined the effectiveness of reducing elective radiotherapy doses to 40 Gy for a consecutive cohort of laryngeal, hypopharyngeal, and p16‐negative oropharyngeal or unknown primary squamous cell carcinomas treated with concurrent chemoradiation. The primary outcome measure was solitary elective nodal recurrence. Results: The cohort included 73 consecutive patients with a median follow up of 23.3 months. There were no cases of solitary elective nodal recurrence. Six patients had locoregional recurrence, eight had distant recurrence, and two had simultaneous locoregional and distant recurrence. All locoregional recurrences occured in the 70 Gy target volume (three in the primary tumor target, three in the involved node target, and two in both). Conclusions: Reduction in elective nodal radiation dose did not lead to solitary elective nodal recurrences for laryngeal, hypopharyngeal, and p16‐negative oropharyngeal cancers.


  • Impact of Surveillance Imaging in Patients With HPV-Associated Oropharyngeal Carcinoma Treated With Definitive Radiation and Chemotherapy

    by Trisha Shang, Gabriel Raab, Linda Chen, Yao Yu, Achraff Shamseddine, Nadeem Riaz, Sean M. McBride, Daphna Gelblum, Luc Gt Morris, Nancy Y. Lee, et al.

    Objectives: Surveillance imaging for HPV-associated oropharyngeal carcinomas (OPCs) differs among physicians and institutions. Surveillance imaging can detect disease progression earlier, but can also contribute to anxiety and cost, without proven survival benefits. We sought to determine practice patterns of surveillance imaging and the number of surveillance scans needed to detect one recurrence in patients with HPV-associated OPCs. Methods: We performed a retrospective cohort study between 2017 and 2019 (median follow-up: 39.9 mo) of consecutive patients with locally advanced HPV-associated OPC who received definitive concurrent chemoradiotherapy (CRT) with 70 Gy at a single institution. Patients were followed post-CRT and their surveillance scans were recorded. Recurrences were classified as detected by first post-treatment scans, surveillance scans, clinical exams, or incidental findings. The number of surveillance scans needed to detect 1 recurrence was determined by dividing the number of surveillance scans by the number of recurrences detected by surveillance scans. Results: Among 276 patients with a median follow-up of 39.9 months, there were 28 recurrences. Of all recurrences, 11 (39.3%) were detected by the first post-treatment scan, 11 (39.3%) by surveillance scan, 5 (17.9%) by clinical exam, and 1 (3.6%) was incidentally found. A total of 694 surveillance scans were taken. The number of surveillance scans needed to detect 1 recurrence was 64 overall, 45 within 2 years, and 248 beyond 2 years from treatment. Conclusions: First post-treatment scans and surveillance scans detected more recurrences than clinical exams. A high burden of surveillance scans is needed to detect 1 recurrence, especially beyond 2 years from treatment.


  • Diabetes Research and Resource Sharing During the COVID-19 Pandemic: A Systematic Review and Experience from an Academic/Non-Profit Resource Website

    by Andrea M. Yeung, Sudha Dirisanala, Amalia Abraham, Jingtong Huang, Grayson M. Brennan, María Agustina Urrutia, Jesica D. Baran, Kevin T. Nguyen, Nicole Y. Xu, Trisha Shang, et al.

    Background: The magnitude of the response of the diabetes professional community to the COVID-19 pandemic is not known. We aimed to examine diabetes technology research trends and resources offered by professional organizations during this period. Methods: We explored patterns of the response from the professional diabetes community to the pandemic by (1) systematically searching for articles related to diabetes, COVID-19, and diabetes technologies; (2) examining publication trends of research protocols (clinicaltrials.gov) and preprints (medRxiv); and (3) reviewing online resources from professional organizations including our website (COVIDinDiabetes.org; an Emory University—Diabetes Technology Society collaboration). Results: We identified 492 articles published between December 2019 and December 2022 meeting our inclusion criteria. Telemedicine and continuous glucose monitoring were the most common reported technologies from most parts of the world. The largest number of preprint articles was published in 2020, with a decline in 2021 and 2022. The number of research protocols related to COVID-19 was the highest in 2020 and declined in 2021 and 2022. Resources from organizations included protocols adapted to treat patients with diabetes and COVID-19, training programs, emergency preparedness, and literature on diabetes and COVID-19. On our website (COVIDinDiabetes.org), there were 12 236 visits and 18 149 pageviews, with 1.6 actions per visits, with most visits coming from North America (N = 7233, 54.2%), South America (N = 2663, 21.8%), and Europe (N = 1219). Conclusions: We conclude that the COVID-19 pandemic promoted unprecedented global research productivity related to diabetes and COVID-19 and that the transition to the use of technology resources has been evident during this period.


  • Open Access

    Contributors

    by David T. Ahn, Mohammed E. Al-Sofiani, Umair Ansari, Julia E. Blanchette, Warris Bokhari, Celeste Campos-Castillo, Sheri R. Colberg, Mercedes Rigla Cros, Sara Donevant, Leslie A. Eiland, et al.

  • Green Diabetes Summit 2021

    by Kevin T. Nguyen, Nicole Y. Xu, Jennifer Y. Zhang, Trisha Shang, Ashley Y. DuBord, Lutz Heinemann, Edward P. Krisiunas, Tobias Stumpe, Donna A. Seid, David C. Klonoff

    On July 21, 2021, Diabetes Technology Society convened the virtual Green Diabetes Summit. The event consisted of 23 representatives from key stakeholder groups based in both the United States and Europe. The purposes of the summit were to (1) provide background on the complexity of addressing sustainability-related issues, including waste management, of diabetes devices from many different perspectives along the products’ life cycle stages, and (2) determine the feasibility and role of a coalition of stakeholders to find solutions, particularly in the design, use, and proper disposal of diabetes devices used in home care that no one stakeholder can resolve on their own.


  • The Diabetes Technology Society Green Declaration

    by Kevin T. Nguyen, Nicole Y. Xu, Jennifer Y. Zhang, Lutz Heinemann, Edward P. Krisiunas, Tobias Stumpe, Donna A. Seid, Rick Bonilla, Laurence Bouret, Weronika Burkot, et al.


  • Continuous Ketone Monitoring Consensus Report 2021

    by Kevin T. Nguyen, Nicole Y. Xu, Jennifer Y. Zhang, Trisha Shang, Ananda Basu, Richard M. Bergenstal, Kristin Castorino, Kong Y. Chen, David Kerr, Suneil K. Koliwad, et al.

    This article is the work product of the Continuous Ketone Monitoring Consensus Panel, which was organized by Diabetes Technology Society and met virtually on April 20, 2021. The panel consisted of 20 US-based experts in the use of diabetes technology, representing adult endocrinology, pediatric endocrinology, advanced practice nursing, diabetes care and education, clinical chemistry, and bioengineering. The panelists were from universities, hospitals, freestanding research institutes, government, and private practice. Panelists reviewed the medical literature pertaining to ten topics: (1) physiology of ketone production, (2) measurement of ketones, (3) performance of the first continuous ketone monitor (CKM) reported to be used in human trials, (4) demographics and epidemiology of diabetic ketoacidosis (DKA), (5) atypical hyperketonemia, (6) prevention of DKA, (7) non-DKA states of fasting ketonemia and ketonuria, (8) potential integration of CKMs with pumps and automated insulin delivery systems to prevent DKA, (9) clinical trials of CKMs, and (10) the future of CKMs. The panelists summarized the medical literature for each of the ten topics in this report. They also developed 30 conclusions (amounting to three conclusions for each topic) about CKMs and voted unanimously to adopt the 30 conclusions. This report is intended to support the development of safe and effective continuous ketone monitoring and to apply this technology in ways that will benefit people with diabetes.